{"id":"NCT01908426","sponsor":"Exelixis","briefTitle":"Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib","officialTitle":"A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-09-26","primaryCompletion":"2017-10-16","completion":"2021-01-12","firstPosted":"2013-07-25","resultsPosted":"2019-03-01","lastUpdate":"2021-05-06"},"enrollment":707,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hepatocellular Carcinoma"],"interventions":[{"type":"DRUG","name":"Cabozantinib tablets","otherNames":["XL184"]},{"type":"DRUG","name":"Placebo tablets","otherNames":[]}],"arms":[{"label":"Cabozantinib (XL184)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the effect of Cabozantinib (XL184) compared with placebo on overall survival in subjects with advanced hepatocellular carcinoma who have received prior sorafenib.","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"Up to 45 months","effectByArm":[{"arm":"Cabozantinib (XL184)","deltaMin":10.2,"sd":null},{"arm":"Placebo","deltaMin":8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0049"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":104,"countries":["United States","Australia","Belgium","Canada","France","Germany","Hong Kong","Ireland","Italy","Netherlands","New Zealand","Poland","Romania","Singapore","South Korea","Spain","Taiwan","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["35487183","35397508","34621044","33822328","32847838","29972759"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":232,"n":467},"commonTop":["Diarrhoea","Fatigue","Decreased appetite","Palmar-plantar erythrodysaesthesia syndrome","Nausea"]}}